Indolent B cell lymphoma

Common Name(s)

Indolent B cell lymphoma

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Indolent B cell lymphoma" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Indolent B cell lymphoma" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Indolent B cell lymphoma" returned 16 free, full-text research articles on human participants. First 3 results:

MicroRNAs as prognostic markers in indolent primary cutaneous B-cell lymphoma.
 

Author(s): Veronica Monsálvez, Santiago Montes-Moreno, María J Artiga, Maria E Rodríguez, Beatriz S Espiridión, Maria Lozano, Ricardo Fernández-de-Misa, Jose L Rodríguez-Peralto, Miguel A Piris, Pablo L Ortíz-Romero

Journal: Mod. Pathol.. 2013 Apr;26(4):617.

 

Last Updated: 1 Apr 2013

Go To URL
Phospho-specific flow cytometry identifies aberrant signaling in indolent B-cell lymphoma.
 

Author(s): Egil S Blix, Jonathan M Irish, Anne Husebekk, Jan Delabie, Lise Forfang, Anne M Tierens, June H Myklebust, Arne Kolstad

Journal:

 

Knowledge about signaling pathways in malignant cells may provide prognostic and diagnostic information in addition to identify potential molecular targets for therapy. B-cell receptor (BCR) and co-receptor CD40 signaling is essential for normal B cells, and there is increasing evidence ...

Last Updated: 11 Dec 2012

Go To URL
MicroRNAs as prognostic markers in indolent primary cutaneous B-cell lymphoma.
 

Author(s): Veronica Monsálvez, Santiago Montes-Moreno, María J Artiga, Maria E Rodríguez, Beatriz Sanchez-Espiridion, Beatriz S Espiridión, Maria Lozano, Ricardo Fernández-de-Misa, Jose L Rodríguez-Peralto, Miguel A Piris, Pablo L Ortíz-Romero

Journal: Mod. Pathol.. 2013 Feb;26(2):171-81.

 

Indolent primary cutaneous B-cell lymphoma is a group of malignant lymphomas comprising marginal zone B-cell lymphoma and centrofollicular B-cell lymphoma. Relapse rate of these tumors is close to 40%, and identifying those patients who are likely to progress remains a challenge. ...

Last Updated: 1 Feb 2013

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Indolent B cell lymphoma" returned 1 free, full-text review articles on human participants. First 3 results:

Advances in molecular biology diagnostic and treatment of B-cell malignancies: indolent B-cell lymphoma.
 

Author(s): M Dreyling, C Buske, W Hiddemann

Journal: Ann. Oncol.. 2005 ;16 Suppl 2():ii99-104.

 

Last Updated: 16 Jun 2005

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in Genetics Home Reference.

There are currently no related results available in GeneReviews.

There are currently no related results available in Genetic Testing Registry.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

A Phase I Trial of DI-B4 in Patients With Advanced CD19 Positive Indolent B-cell Malignancies
 

Status: Recruiting

Condition Summary: Indolent B-cell Lymphoma; Chronic Lymphocytic Leukaemia

 

Last Updated: 18 Feb 2014

Go to URL
Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma
 

Status: Recruiting

Condition Summary: Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Nodal Marginal Zone B-cell Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Splenic Marginal Zone Lymphoma; Waldenström Macroglobulinemia

 

Last Updated: 24 Jul 2014

Go to URL